Clinical Trial Update: Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of radiation therapy with a DLL3-targeting bispecific T-cell engager in DLL3-expressing tumors. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Glioblastoma
• Medullary Thyroid Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Olfactory Neuroblastoma
• Sinonasal Undifferentiated Carcinoma
• Testicular Cancer

Snippet

Sponsor: University of Arizona | Conditions: Melanoma, Medullary Thyroid Cancer | Phase 1, Phase 2 | Status: RECRUITING